Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Moderate Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $195.00.

A number of analysts have issued reports on ASND shares. TD Cowen decreased their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Citigroup upped their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Bank of America upped their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $142.67 on Tuesday. The firm has a market cap of $8.31 billion, a PE ratio of -14.85 and a beta of 0.64. The firm has a 50 day simple moving average of $135.44 and a 200-day simple moving average of $136.41. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -7.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new position in Ascendis Pharma A/S in the 4th quarter valued at about $78,719,000. GSA Capital Partners LLP purchased a new position in Ascendis Pharma A/S in the first quarter valued at about $992,000. Price T Rowe Associates Inc. MD grew its stake in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth approximately $5,779,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $16,648,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.